Thrombocytopenia or haemorrhage5 (Subnet based on 13 studies including 2744 participants) · patients at any age with solid cancer or haematological malignancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia or haemorrhage5 (Subnet based on 13 studies including 2744 participants) · patients at any age with solid cancer or haematological malignancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: clinically relevant non‐major bleeding / heparin‐induced thrombocytopenia ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Thrombocytopenia compared with no bortezomib (low certainty).
3 findings from 1 review
OR 2.05 [1.7, 2.48]
8 studies · 3791 participants
Low
OR 1.51 [1.13, 2]
3 studies · 1196 participants
High
OR 2.6 [2.01, 3.35]
5 studies · 2595 participants
Low
Intervention not reported
Incidence of febrile neutropenia · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Incidence of febrile neutropenia · cancer patients receiving myelotoxic chemotherapy
It is very uncertain whether the intervention changes incidence of febrile neutropenia (very low certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF
Ruxolitinib showed no clear difference in safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4… compared with best available therapy (low certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF
Ruxolitinib may leads to higher safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4… compared with placebo (low certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · Patients with treating MF
Ruxolitinib may leads to higher safety (AE, adverse drug reaction): neutropenia Grades 3 or 4… compared with placebo (low certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · adults receiving treatment for follicular lymphoma
It is very uncertain whether ACR changes neutropenia grade 3‐4 compared with non‐ACR (very low certainty).
1 finding from 1 review
Intervention not reported
Episodes of febrile neutropenia · patients with prevention and treatment of infectious complications in patients with acute myelogenous leukemia
The intervention showed no clear difference in episodes of febrile neutropenia (moderate certainty).
1 finding from 1 review
Major procedure‐related bleeding · thrombocytopenia
1 finding from 1 review
All‐cause mortality up to 30 days after the procedure · thrombocytopenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Transfusion‐related complications within 24 hours of the procedure · thrombocytopenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Procedure‐related (lumbar puncture or epidural anaesthetic) complications within 7 days of the procedure · thrombocytopenia
1 finding from 1 review
Quality of life (as defined by the individual studies) · thrombocytopenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All‐cause mortality · patients with solid tumours without thrombocytopenia before chemotherapy
The intervention showed no clear difference in all‐cause mortality (low certainty).
1 finding from 1 review
Intervention not reported
Number of patients with at least one severe/life‐threatening bleeding episode · patients with solid tumours with thrombocytopenia during chemotherapy
1 finding from 1 review
Intervention not reported
Number of treatment cycles with at least one bleeding episode ‐ not measured · patients with solid tumours with thrombocytopenia during chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of days on which bleeding occurred ‐ not measured · patients with solid tumours with thrombocytopenia during chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found